0001013762-23-000416.txt : 20231002
0001013762-23-000416.hdr.sgml : 20231002
20231002160008
ACCESSION NUMBER: 0001013762-23-000416
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230929
FILED AS OF DATE: 20231002
DATE AS OF CHANGE: 20231002
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yang Weiguang
CENTRAL INDEX KEY: 0001799603
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40608
FILM NUMBER: 231299506
MAIL ADDRESS:
STREET 1: NANXI CREATIVE CENTER, SUITE 218
STREET 2: 841 YAN AN MIDDLE ROAD, JING AN DISTRICT
CITY: SHANGHAI
STATE: F4
ZIP: 200040
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Estrella Immunopharma, Inc.
CENTRAL INDEX KEY: 0001844417
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 861314502
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5858 HORTON STREET, SUITE 170
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: (510) 318-9098
MAIL ADDRESS:
STREET 1: 5858 HORTON STREET, SUITE 170
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: TradeUP Acquisition Corp.
DATE OF NAME CHANGE: 20210204
4
1
ownership.xml
X0508
4
2023-09-29
1
0001844417
Estrella Immunopharma, Inc.
ESLA
0001799603
Yang Weiguang
437 MADISON AVENUE, 27TH FLOOR
NEW YORK
NY
10022
0
0
0
1
Former Co-CEO and Director
0
In connection with the consummation of the initial business combination of Tradeup Acquisition Corp. ("UPTD", together with its successor, Estrella Immunopharma, Inc., the "Issuer") pursuant to certain business combination agreement by and among UPTD, Tradeup Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of UPTD, and Estrella Biopharma, Inc., a Delaware corporation ("Estrella"), UPTD changed its name to Estrella Immunopharma, Inc.
This "Exit" Form 4 is voluntarily filed to report that the Reporting Person is no longer serving in the role as the Issuer's co-CEO and director effectively or holding more than 10% of issued and outstanding shares of the Issuer after September 29, 2023, and is therefore no longer subject to Section 16 Reporting.
/s/ Weiguang Yang
2023-10-02